GL1X · GenesisL1 explorer

MolNFT v1 · #77764 · protein

Crystal structure of human CD38 in complex with compound cz-48

3ROM · ADP-ribosyl cyclase 1: “Crystal structure of human CD38 in complex with compound cz-48”. X-ray diffraction, 1 ligand (48Z), 7 pockets (best druggability 0.73). MolNFT v1 #77764 on GenesisL1: 3D structure, binding sites and pockets…

PDB
3ROM
Type
protein
Length
505 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
ADP-ribosyl cyclase 1
EC
3.2.2.5
UniProt
P28907
Ligands
48Z
Pockets
7 · best druggability 0.73

Structure

x-ray diffraction · 2 distinct chains · 42% helix, 14% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AADP-ribosyl cyclase 1 (EC 3.2.2.5)protein25242% helix, 14% strandP28907
BADP-ribosyl cyclase 1 (EC 3.2.2.5)protein25342% helix, 13% strandP28907

Ligands and binding sites

  • 48Z · 2-deoxy-2-fluoro-5-O-thiophosphono-alpha-D-arabinofuranose · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16200.730.807348Z
22870.610.793648Z
3680.560.8814empty
41040.520.8215empty
5820.380.7716empty

Interfaces

1 interface between chains.

  • A–B · 680 Ų buried · 15 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 12 disulfide, 2 covalent (disulfide, covalent ligand).

Compared structures

  • 3ROM · Crystal structure of human CD38 in complex with compound CZ-48 · the same entry in another collection · chain A against A, TM-score 1.00
  • P28907 · AlphaFold monomer V2.0 prediction for ADP-ribosyl CYCLASE/CYCLIC ADP- ribose hydrolase 1… · a predicted model of the same protein · chain B against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.